Two New Studies Provide Real World Data on Cardiovascular Events in CRESTOR Users

"These pharmacoepidemiological studies add to the extensive knowledge we have gathered through the CRESTOR clinical trials program, which continues to show that CRESTOR offers outstanding effects on lowering LDL-C with the additional benefit of raising HDL-C," said Elisabeth Bjork, CRESTOR Medical Science Director at AstraZeneca.

The first study conducted in the Netherlands, compared the differences in incidences of hospitalisations for cardiovascular events -- including fatal and non-fatal ischaemic heart disease and stroke- between users of selected statins (rosuvastatin, simvastatin, atorvastatin, pravastatin). 76,147 statin-naive patients from the PHARMO Institute database, who had not experienced cardiovascular events in the preceding year were followed for up to two years, with a median duration of therapy of eleven months.